UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

The European respiratory journal, 2009-04, Vol.33 (4), p.785-792

2009

Volltextzugriff (PDF)

Short-Term Venoarterial Extracorporeal Membrane Oxygenation for Endobronchial Hemorrhage after Pulmonary Endarterectomy

The Journal of heart and lung transplantation, 2016-04, Vol.35 (4), p.S148-S149

2016

Volltextzugriff (PDF)

Noninvasive detection of early pulmonary vascular dysfunction in scleroderma

Respiratory medicine, 2009-11, Vol.103 (11), p.1713-1718

2009

Volltextzugriff (PDF)

Nocturnal periodic breathing in primary pulmonary hypertension

The European respiratory journal, 2002-04, Vol.19 (4), p.658-663

2002

Volltextzugriff (PDF)

Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study

The Journal of heart and lung transplantation, 2016-04, Vol.35 (4), p.S120-S120

2016

Volltextzugriff (PDF)

Riociguat for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH): Responder Analysis of Who Functional Class III Patients from the Patent-1 Study

Value in health, 2013-11, Vol.16 (7), p.A513-A513

2013

Volltextzugriff (PDF)

OP0267 Initial Combination Therapy of Ambrisentan and Tadalafil in Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH): Subgroup Analysis from the Ambition Trial

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.173-173

2015

Volltextzugriff (PDF)

Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species

Free radical biology & medicine, 2012-03, Vol.52 (6), p.1033-1042

2012

Volltextzugriff (PDF)

Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension

The European respiratory journal, 2001-01, Vol.17 (1), p.14-19

2001

Volltextzugriff (PDF)

Reduction Of Pulmonary Arterial Hypertension (Pah)-Related Hospitalizations With Macitentan In The Randomized Controlled Trial Seraphin

Value in health, 2013-05, Vol.16 (3), p.A231-A231

2013

Volltextzugriff (PDF)

Analysis of Risk Assessment Tools in the REPLACE Study

The Journal of heart and lung transplantation, 2021-04, Vol.40 (4), p.S465-S465

2021

Volltextzugriff (PDF)

Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study

The Journal of heart and lung transplantation, 2019-04, Vol.38 (4), p.S96-S96

2019

Volltextzugriff (PDF)

Inflammation, immunological reaction and role of infection in pulmonary hypertension

Clinical microbiology and infection, 2011-01, Vol.17 (1), p.7-14

2011

Volltextzugriff (PDF)

Validation of REVEAL Risk Score Calculator 2.0 in Patients with CTEPH in the Phase III CHEST Study

The Journal of heart and lung transplantation, 2020-04, Vol.39 (4), p.S32-S33

2020

Volltextzugriff (PDF)

Validation of REVEAL Risk Score Calculator 2.0 in Patients with PAH in the Phase III PATENT Study

The Journal of heart and lung transplantation, 2020-04, Vol.39 (4), p.S18-S18

2020

Volltextzugriff (PDF)

Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders

The European respiratory journal, 2002-04, Vol.19 (4), p.664-671

2002

Volltextzugriff (PDF)

(502) - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis

The Journal of heart and lung transplantation, 2018-04, Vol.37 (4), p.S207-S208

2018

Volltextzugriff (PDF)

The role of Mitochondrial Superoxide Release in Acute and Chronic Hypoxia Sensing and Signaling of the Pulmonary vasculature

Biochimica et biophysica acta. Bioenergetics, 2018-09, Vol.1859, p.e90-e91

2018

Volltextzugriff (PDF)

PCV7 - Riociguat for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH): Responder Analysis of Who Functional Class III Patients from the Patent-1 Study

Value in health, 2013-11, Vol.16 (7), p.A513-A513

2013

Volltextzugriff (PDF)

Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure

The European respiratory journal, 2003-08, Vol.22 (2), p.342-347

2003

Volltextzugriff (PDF)

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations

Respiratory research, 2011-07, Vol.12 (102), p.99-99, Article 99

2011

Volltextzugriff (PDF)

Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension

Cerebrovascular diseases (Basel, Switzerland), 2006-01, Vol.21 (3), p.194-200

2006

Volltextzugriff (PDF)

Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study

Herzschrittmachertherapie & Elektrophysiologie, 2015-06, Vol.26 (2), p.155-162

2015

Volltextzugriff (PDF)

Increased pulmonary vascular remodeling in UCP2 deficiency

Biochimica et biophysica acta. Bioenergetics, 2012-10, Vol.1817, p.S46-S46

2012

Volltextzugriff (PDF)

Stem cell‐mediated natural tissue engineering

Journal of cellular and molecular medicine, 2011-01, Vol.15 (1), p.52-62

2011

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)

Sprache

Erscheinungsjahr

n.n

Thema

Pulmonary Hypertension
(11)
Humans
(9)
Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Hypertension, Pulmonary - Physiopathology
(7)
Male
(7)
Middle Aged
(7)
Cardiology
(6)
Female
(6)
Internal Medicine
(6)
Respiratory System
(6)
Adult
(5)
Aged
(5)
Medicine
(5)
Medicine & Public Health
(5)
Biological And Medical Sciences
(4)
Hypertension
(4)
Medical Sciences
(4)
Administration, Inhalation
(3)
Animals
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

Short-Term Venoarterial Extracorporeal Membrane Oxygenation for Endobronchial Hemorrhage after Pulmonary Endarterectomy

Noninvasive detection of early pulmonary vascular dysfunction in scleroderma

Nocturnal periodic breathing in primary pulmonary hypertension

Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study

Riociguat for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH): Responder Analysis of Who Functional Class III Patients from the Patent-1 Study

OP0267 Initial Combination Therapy of Ambrisentan and Tadalafil in Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH): Subgroup Analysis from the Ambition Trial

Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species

Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension

Reduction Of Pulmonary Arterial Hypertension (Pah)-Related Hospitalizations With Macitentan In The Randomized Controlled Trial Seraphin

Analysis of Risk Assessment Tools in the REPLACE Study

Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study

Inflammation, immunological reaction and role of infection in pulmonary hypertension

Validation of REVEAL Risk Score Calculator 2.0 in Patients with CTEPH in the Phase III CHEST Study

Validation of REVEAL Risk Score Calculator 2.0 in Patients with PAH in the Phase III PATENT Study

Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders

(502) - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis

The role of Mitochondrial Superoxide Release in Acute and Chronic Hypoxia Sensing and Signaling of the Pulmonary vasculature

PCV7 - Riociguat for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH): Responder Analysis of Who Functional Class III Patients from the Patent-1 Study

Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations

Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension

Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study

Increased pulmonary vascular remodeling in UCP2 deficiency

Stem cell‐mediated natural tissue engineering

Suchergebnisse filtern